By Conjoint Professor Anthony Michael Joshua

Journal articles

Joshua AM; Evren S; Zannella VE; Bowes B; Fleshner NE; Jewett MAS; Finelli A; Evans A; Koritzinsky M; Sweet J; Pollak MN, 2012, 'A phase II trial of neoadjuvant metformin in prostatic adenocarcinoma with serum and tissue biomarker evaluation.', Journal of Clinical Oncology, 30, pp. e15118 - e15118, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e15118

Chi KN; Hotte SJ; Ellard S; Gingerich JR; Joshua AM; Yu EY; Gleave ME, 2012, 'A randomized phase II study of OGX-427 plus prednisone (P) versus P alone in patients (pts) with metastatic castration resistant prostate cancer (CRPC).', Journal of Clinical Oncology, 30, pp. 4514 - 4514, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.4514

Montgomery RB; Joshua A; Hannah AL; Peterson AC; Lopez C; Gleave ME; Taplin M-E, 2012, 'A randomized, open-label, phase II study of MDV3100 alone or in combination with leuprolide and dutasteride as neoadjuvant therapy to prostatectomy in intermediate and high-risk prostate cancer.', Journal of Clinical Oncology, 30, pp. TPS4695 - TPS4695, http://dx.doi.org/10.1200/jco.2012.30.15_suppl.tps4695

Niraula S; Chi K; Joshua AM, 2012, 'Beyond Castration-Defining Future Directions in the Hormonal Treatment of Prostate Cancer', Hormones and Cancer, 3, pp. 3 - 13, http://dx.doi.org/10.1007/s12672-011-0096-0

Fraser M; Zhao H; Luoto KR; Lundin C; Coackley C; Chan N; Joshua AM; Bismar TA; Evans A; Helleday T; Bristow RG, 2012, 'PTEN deletion in prostate cancer cells does not associate with loss of RAD51 function: Implications for radiotherapy and chemotherapy', Clinical Cancer Research, 18, pp. 1015 - 1027, http://dx.doi.org/10.1158/1078-0432.CCR-11-2189

Joshua AM; Fleshner N; Pollak M; Zannella V; Bowes B; Koritzinsky M; Sweet J; Evans A; Trachtenberg J; Jewett M; Finelli A, 2012, 'Abstract A15: A phase 2 study of neoadjuvant metformin in prostatic carcinoma', Cancer Research, 72, pp. A15 - A15, http://dx.doi.org/10.1158/1538-7445.prca2012-a15

Morin E; Mete O; Wasserman JD; Joshua AM; Asa SL; Ezzat S, 2012, 'Carney complex with adrenal cortical carcinoma', Journal of Clinical Endocrinology and Metabolism, 97, pp. E202 - E206, http://dx.doi.org/10.1210/jc.2011-2321

Joshua AM, 2012, 'Melanoma prevention: Are we doing enough? A Canadian perspective', Current Oncology, 19, pp. e462 - e467, http://dx.doi.org/10.3747/co.19.1222

Chi K; Yu EY; Ellard S; Hotte SJ; Gingerich JR; Joshua AM; Gleave ME, 2012, 'A Randomized Phase II Study of OGX-427 Plus Prednisone (P) Vs. P Alone in Patients (PTS) with Metastatic Castration Resistant Prostate Cancer (CRPC)', Annals of Oncology, 23, pp. ix297 - ix297, http://dx.doi.org/10.1016/s0923-7534(20)33525-0

Joshua AM; Shen E; Yoshimoto M; Marrano P; Zielenska M; Evans AJ; Van Der Kwast T; Squire JA, 2011, 'Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies', Prostate, 71, pp. 778 - 790, http://dx.doi.org/10.1002/pros.21294

Squire JA; Park PC; Yoshimoto M; Alami J; Williams JL; Evans A; Joshua AM, 2011, 'Prostate Cancer as a Model System for Genetic Diversity in Tumors', , 112, pp. 183 - 216, http://dx.doi.org/10.1016/B978-0-12-387688-1.00007-7

Joshua A; Evans A; Squire J; Yoshimoto M; Ludkovski O; Tan S-H; Dobi A; Furusato B; Petrovics G; Srivastava S; Sesterhenn I, 2011, '133 EVALUATION OF PTEN AND TMPRSS2-ERG ABNORMALITIES IN PROSTATE CANCER BY FISH AND IMMUNOHISTOCHEMISTRY TO ADDRESS INTRA- AND INTER- TISSUE HETEROGENEITY AND DISEASE PROGRESSION', Journal of Urology, 185, http://dx.doi.org/10.1016/j.juro.2011.02.200

Nguyen LT; Yen PH; Nie J; Liadis N; Ghazarian D; Al-Habeeb A; Easson A; Leong W; Lipa J; McCready D; Reedijk M; Hogg D; Joshua AM; Quirt I; Messner H; Shaw P; Crump M; Sharon E; Ohashi PS, 2010, 'Expansion and characterization of human melanoma tumor-infiltrating lymphocytes (TILs)', Plos One, 5, http://dx.doi.org/10.1371/journal.pone.0013940

Chung C; Dawson LA; Joshua AM; Brade AM, 2010, 'Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: Sunitinib and sorafenib', Anti Cancer Drugs, 21, pp. 206 - 209, http://dx.doi.org/10.1097/CAD.0b013e328333d679

Sahi C; Knox JJ; Clemons M; Joshua AM; Broom R, 2010, 'Renal cell carcinoma bone metastases: Clinical advances', Therapeutic Advances in Medical Oncology, 2, pp. 75 - 83, http://dx.doi.org/10.1177/1758834009358417

Lara-Guerra H; Waddell TK; Salvarrey MA; Joshua AM; Chung CT; Paul N; Boerner S; Sakurada A; Ludkovski O; Ma C; Squire J; Liu G; Shepherd FA; Tsao MS; Leighl NB, 2009, 'Phase II study of preoperative gefitinib in clinical stage I non-small-cell lung cancer', Journal of Clinical Oncology, 27, pp. 6229 - 6236, http://dx.doi.org/10.1200/JCO.2009.22.3370

Joshua AM; Marrano P; Evans A; Van der Kwast T; Zielenska M; Squire J, 2009, 'Topographical analysis of telomere length and correlation with genomic instability in whole mount prostatectomies', Journal of Clinical Oncology, 27, pp. 11107 - 11107, http://dx.doi.org/10.1200/jco.2009.27.15_suppl.11107

Joshua AM; Ezzat S; Asa SL; Evans A; Broom R; Freeman M; Knox JJ, 2009, 'Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma', Journal of Clinical Endocrinology and Metabolism, 94, pp. 5 - 9, http://dx.doi.org/10.1210/jc.2008-1836

Joshua AM; Evans A; Van der Kwast T; Zielenska M; Meeker AK; Chinnaiyan A; Squire JA, 2008, 'Prostatic preneoplasia and beyond', Biochimica Et Biophysica Acta Reviews on Cancer, 1785, pp. 156 - 181, http://dx.doi.org/10.1016/j.bbcan.2007.12.001

Yoshimoto M; Joshua AM; Cunha IW; Coudry RA; Fonseca FP; Ludkovski O; Zielenska M; Soares FA; Squire JA, 2008, 'Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome', Modern Pathology, 21, pp. 1451 - 1460, http://dx.doi.org/10.1038/modpathol.2008.96

Joshua AM; Boutros PC, 2008, 'Web-based resources for clinical bioinformatics.', Methods in Molecular Medicine, 141, pp. 309 - 329, http://dx.doi.org/10.1007/978-1-60327-148-6_17

Joshua AM; Vukovic B; Braude I; Hussein S; Zielenska M; Srigley J; Evans A; Squire JA, 2007, 'Telomere attrition in isolated high-grade prostatic intraepithelial neoplasia and surrounding stroma is predictive of prostate cancer', Neoplasia, 9, pp. 81 - 89, http://dx.doi.org/10.1593/neo.06745

Joshua A; Vukovic B; Braude I; Fleshner NE; Hussein S; Srigley J; Evans A; Zielenska M; Squire J, 2007, '654: Telomere Length Analysis of High-Grade Prostatic Intrapeithelial Neoplasia and Surrounding Stroma Predicts Outcome to Prostate Cancer', Journal of Urology, 177, pp. 220 - 220, http://dx.doi.org/10.1016/s0022-5347(18)30894-2

Dalla-Torre CA; Yoshimoto M; Lee CH; Joshua AM; de Toledo SRC; Petrilli AS; Andrade JAD; Chilton-MacNeill S; Zielenska M; Squire JA, 2006, 'Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma', BMC Cancer, 6, http://dx.doi.org/10.1186/1471-2407-6-237

Yoshimoto M; Cutz JC; Nuin PAS; Joshua AM; Bayani J; Evans AJ; Zielenska M; Squire JA, 2006, 'Interphase FISH analysis of PTEN in histologic sections shows genomic deletions in 68% of primary prostate cancer and 23% of high-grade prostatic intra-epithelial neoplasias', Cancer Genetics and Cytogenetics, 169, pp. 128 - 137, http://dx.doi.org/10.1016/j.cancergencyto.2006.04.003

Yoshimoto M; Joshua AM; Chilton-Macneill S; Bayani J; Prasad M; Fleshner N; Finelli A; Evans A; Sweet J; Squire J; Zielenska M, 2006, 'Detection of novel variant TMPRSS2 /ERG fusion transcripts suggests independent genomic alterations may underlie origin of multi-centric prostate cancer', Journal of Clinical Oncology, 24, pp. 10029 - 10029, http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10029

Joshua AM; Vukovic B; Braude I; Evans A; Srigley J; Squire JA, 2006, 'Telomere dysfunction in prostatic carcinogenesis', Journal of Clinical Oncology, 24, pp. 10021 - 10021, http://dx.doi.org/10.1200/jco.2006.24.18_suppl.10021

Nordman IC; Iyer S; Joshua AM; Clarke SJ, 2006, 'Advances in the adjuvant treatment of colorectal cancer', ANZ Journal of Surgery, 76, pp. 373 - 380, http://dx.doi.org/10.1111/j.1445-2197.2006.03726.x

Yoshimoto M; Joshua AM; Chilton-MacNeill S; Bayani J; Selvarajah S; Evans AJ; Zielenska M; Squire JA, 2006, 'Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement', Neoplasia, 8, pp. 465 - 469, http://dx.doi.org/10.1593/neo.06283

Joshua AM; Cotroneo A; Clarke S, 2005, 'Humor and oncology', Journal of Clinical Oncology, 23, pp. 645 - 648, http://dx.doi.org/10.1200/JCO.2005.09.064

Vardy J; Joshua AM; Clarke SJ; Yarrow PM; Lin BPC, 2005, 'Small blue cell tumors of the rectum: CASE 1. Erwing's sarcoma of the rectum', Journal of Clinical Oncology, 23, pp. 910 - 912, http://dx.doi.org/10.1200/JCO.2005.03.096

Joshua AM; Adams D; McKenzie P; Solomon M; Clarke SJ, 2005, 'Small blue cell tumors of the rectum: CASE 2. Small-cell carcinoma of the rectum', Journal of Clinical Oncology, 23, pp. 912 - 913, http://dx.doi.org/10.1200/JCO.2005.03.094

Joshua AM; Nordman I; Venkataswaran R; Clarke S; Stockler MR; Boyer M, 2005, 'Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer', Internal Medicine Journal, 35, pp. 468 - 472, http://dx.doi.org/10.1111/j.1445-5994.2005.00883.x

Millward MJ; Joshua A; Kefford R; Aamdal S; Thomson D; Hersey P; Toner G; Lynch K, 2005, 'Multi-centre Phase II trial of the polyamine synthesis inhibitor SAM486A (CGP48664) in patients with metastatic melanoma', Investigational New Drugs, 23, pp. 253 - 256, http://dx.doi.org/10.1007/s10637-005-6734-z

Joshua AM; Celermajer DS; Stockler MR, 2005, 'Beauty is in the eye of the examiner: Reaching agreement about physical signs and their value', Internal Medicine Journal, 35, pp. 178 - 187, http://dx.doi.org/10.1111/j.1445-5994.2004.00795.x

Joshua AM; Boyer MJ; Subramanian R; Clarke SJ, 2005, 'Smoking reduction does work: Resulting alterations in the incidence and histological subtypes of lung cancer in New South Wales in the last 20 years', Respirology, 10, pp. 233 - 238, http://dx.doi.org/10.1111/j.1440-1843.2005.00672.x

BURGE ME; JOSHUA AM; McNEIL CM; HUI R; BOYER MJ; ABRAHAM R, 2005, 'Retrospective review of pemetrexed with or without platinum in malignant mesothelioma: The Australian ‘Special Access Scheme’ experience', Asia-Pacific Journal of Clinical Oncology, 1, pp. 47 - 52, http://dx.doi.org/10.1111/j.1743-7563.2005.00006.x

Joshua AM; Nordman I; Venkataswaran R; Stockler M; Boyer M; Clarke S, 2005, 'Weekly docetaxel as second line treatment after mitoxantrone for androgen-independent prostate cancer (AIPC)', Journal of Clinical Oncology, 23, pp. 4713 - 4713, http://dx.doi.org/10.1200/jco.2005.23.16_suppl.4713

Joshua AM; Burge ME; McNeil CM; Hui R; Boyer MJ; Abraham R, 2004, 'An Australian experience of pemetrexed in malignant mesothelioma (MM)', Journal of Clinical Oncology, 22, pp. 7285 - 7285, http://dx.doi.org/10.1200/jco.2004.22.90140.7285

Joshua AM; Burge ME; McNeil CM; Hui R; Boyer MJ; Abraham R, 2004, 'An Australian experience of pemetrexed in malignant mesothelioma (MM)', Journal of Clinical Oncology, 22, pp. 7285 - 7285, http://dx.doi.org/10.1200/jco.2004.22.14_suppl.7285

Joshua AM; Stockler MR; Boyer MJ, 2004, 'Prolonged survival after the diagnosis of metastatic hepatic epitheliod haemangioendothelioma [1]', Internal Medicine Journal, 34, pp. 70 - 71, http://dx.doi.org/10.1111/j.1444-0903.2004.00514.x

Joshua AM; Carter JR; Beale P, 2004, 'The use of taxanes in choriocarcinoma; a case report and review of the literature', Gynecologic Oncology, 94, pp. 581 - 583, http://dx.doi.org/10.1016/j.ygyno.2004.05.036

Bennett S; Joshua A; Russell PJ, 1997, 'Reliable method of isolating transfected clones from the LNCaP human prostatic cell line', Biotechniques, 23, pp. 66 - 70, http://dx.doi.org/10.2144/97231bm13

Bennett S; Unknown ; Russell PJ, 1997, 'Isolation of transfected clones from the LNCaP human prostatic cell line', BioTechniques, pp. 66 - 68

Richter S; Ruether JD; Wood L; Canil C; Moretto P; Venner P; Gingerich J; Emmenegger U; Eisen A; Zalewski P; Joshua A; Mukherjee SD; Heng D; Czaykowski P; Soulieres D; Blais N; Rendon R; Fleshner N; Crook JM; Sridhar SS, 'Management of carcinoma of the penis: Consensus statement from the Canadian Association of Genitourinary Medical Oncologists (CAGMO)', CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 7, pp. E797 - E811, http://dx.doi.org/10.5489/cuaj.1794

Conference Papers

Gillessen S; Turco F; Davis ID; Efstathiou JA; Fizazi K; James ND; Shore N; Small E; Smith M; Sweeney CJ; Tombal B; Zilli T; Agarwal N; Antonarakis ES; Aparicio A; Armstrong AJ; Bastos DA; Attard G; Axcrona K; Ayadi M; Beltran H; Bjartell A; Blanchard P; Bourlon MT; Briganti A; Bulbul M; Buttigliero C; Caffo O; Castellano D; Castro E; Cheng HH; Chi KN; Clarke CS; Clarke N; de Bono JS; De Santis M; Duran I; Efstathiou E; Ekeke ON; El Nahas TIH; Emmett L; Fanti S; Fatiregun OA; Feng FY; Fong PCC; Fonteyne V; Fossati N; George DJ; Gleave ME; Gravis G; Halabi S; Heinrich D; Herrmann K; Hofman MS; Hope TA; Horvath LG; Hussain MHA; Jereczek-Fossa BA; Jones RJ; Joshua AM; Kanesvaran R; Keizman D; Khauli RB; Kramer G; Loeb S; Mahal BA; Maluf FC; Mateo J; Matheson D; Matikainen MP; McDermott R; McKay RR; Mehra N; Merseburger AS; Morgans AK; Morris MJ; Mrabti H; Mukherji D; Murphy DG; Murthy V; Mutambirwa SBA; Nguyen PL; Oh WK; Ost P; O'Sullivan JM; Padhani AR; Parker C; Poon DMC; Pritchard CC; Rabah DM; Rathkopf D; Reiter RE; Renard-Penna R; Ryan CJ; Saad F; Sade JP; Sandhu S; Sartor OA; Schaeffer E; Scher HI, 2025, 'Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)', in European Urology, pp. 157 - 216, http://dx.doi.org/10.1016/j.eururo.2024.09.017

Sathekge M; Crumbaker M; Joshua AM; Bruchertseifer F; Kreisl T; Emineni S; Wehbe J; Korn M; Morgenstern A; Emmett L, 2023, 'AcTION: A phase 1 study of [²²⁵Ac]Ac-PSMA-617 in men with PSMA-positive prostate cancer with or without prior [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, AUSTRIA, Vienna, pp. S152 - S153, presented at Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), AUSTRIA, Vienna, 09 September 2023 - 13 September 2023

Li S; Nguyen A; Counter W; John N; De Leon J; Hruby G; Joshua AM; Stricker P; Wong K; Liu V; Lengyelova E; Agrawal S; Emmett L, 2023, 'Detection Rate of ⁶⁴Cu-SAR-Bombesin-PET/CT in Men with Biochemically Recurrent Prostate Cancer and Negative or Equivocal ⁶⁸Ga-PSMA-11-PET/CT', in EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, SPRINGER, AUSTRIA, Vienna, pp. S181 - S181, presented at Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), AUSTRIA, Vienna, 09 September 2023 - 13 September 2023

Horvath L; Lin H-M; Huynh K; Meikle T; Joshua AM; Azad A; Tan W; Butler L; Meikle P, 2023, 'Circulating ether lipids in prostate cancer', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Hamid A; Gupta S; Keerthikumar S; Pasam A; Crumbaker M; Joshua AM; Lam E; Wenstrup R; Emmett L; Goode DL; Hofman MS; Sandhu S, 2023, 'Circulating tumor cells (CTCs) in patients with metastatic castration resistant prostate cancer (mCRPC) treated with olaparib plus ¹⁷⁷lutetium-prostate specific membrane antigen-617 (¹⁷⁷Lu-PSMA-617) in the LuPARP trial', in JOURNAL OF CLINICAL ONCOLOGY, LIPPINCOTT WILLIAMS & WILKINS, IL, Chicago, presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), IL, Chicago, 02 June 2023 - 06 June 2023

Back to profile page